This finding suggests that the ASAP score, which was designed for HCC detection in patients with low AFP levels, is as effective as GALAD in discriminating early-stage HCC from cirrhosis, a finding that requires further validation in prospectively designed trials. The gene discussed is AFP; the disease is hepatocellular carcinoma.